Auranofin tablets 3 mg for rheumatoid arthritis (Ridaura)
Product Code :
Availability : 10
General information on Japanese Auranofin tablets 3 mg for rheumatoid arthritis (Ridaura)
Package details: 100 tablets
Manufacturer: Sawai Pharmaceutical Co., Ltd., Japan
Active ingredients: auranofin (chemical formula C20H34AuO9PS0)
Medical effect: Auranofin tablets are effective for the treatment of rheumatoid arthritis.
Contraindications and precautions: do not use for pregnant or breastfeeding women.
Please note that this drug is slow-acting. The effect usually appears after 1-3 months of treatment, but in some cases, the effect is seen after 6 months. The patient should take it continuously for at least 3 months.
If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.
Dosage and administration
For adults: take 1 tablet (3 mg of auranofin) at a time, 2 times a day after meals in the morning and evening. The maximum dosage of 2 tablets (6 mg) a day should not be exceeded.
How effective are Auranofin tablets 3 mg from Japan for rheumatoid arthritis (Ridaura)?
Auranofin is a gold salt and a disease-modifying antirheumatic drug. While it does not treat the reason of the disease, it improves the condition of the patient by the following ways:
- bringing the abnormalities of immune function closer to normal,
- decreasing inflammation of joints,
- decreasing swelling of joints,
- improving morning stiffness,
- decreasing pain and allowing to use fewer oral painkillers.
Who should use Auranofin tablets 3 mg from Japan?
Auranofin is used for the treatment of rheumatoid arthritis, particularly in cases of severe disease when a patient does not respond to other treatment or cannot take other medications. While it may cause some gastrointestinal side effects, studies show that it’s significantly safe than injectable gold thiolates like gold sodium thiomalate and gold thioglucose due to its oral bioavailability (D. T. Felson, J. J. Anderson, R. F. Meenan. "The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses". Arthritis and Rheumatism, 1990, 33 (10): 1449–61).